What is the clinical effect of Vebreltinib?

Vebreltinib (vebreltinib) is a new type of highly selective MET tyrosine kinase inhibitor (MET-TKI) that has shown outstanding clinical efficacy in multiple international studies, especially in MET exon 14 skipping (METex14 Skipping) typenon-small cell lung cancer(NSCLC) performed brilliantly. This drug is one of the few MET-targeted drugs that also has the ability to penetrate the central nervous system, which means that it can not only control primary lung lesions, but also have a significant effect on brain metastases.

In clinical practice, boricitinib has been proven to effectively inhibitabnormal activation of the MET signaling pathway and block the proliferation and metastasis of tumor cells. Overseas studies have pointed out that its objective response rate (ORR) and disease control rate (DCR) are at a higher level among similar drugs, and the response lasts longer. Especially among patients who have failed previous treatments, bricitinib has shown a clear trend of tumor shrinkage. Many patients have improved symptoms within a few weeks of treatment, including reduced cough, improved dyspnea and restored appetite. Because the drug has good oral absorption properties and a low risk of drug interactions, it also provides convenience for long-term use.

What is more noteworthy is that bricitinib has also made breakthrough progress in the research of brain glioma. For patients with astrocytoma carrying the PTPRZ1-MET fusion gene, the drug can inhibit tumor growth by inhibiting abnormal MET signaling. Clinical data show that some patients experienced significant lesion shrinkage and neurological symptom relief after taking the drug, suggesting that it has central anti-tumor activity.

From a safety perspective, bricitinib is well tolerated. The most common adverse reactions are mild to moderate fatigue, nausea, elevated transaminases, and mild edema, and most are reversible reactions. Compared with traditional chemotherapy, the incidence of side effects is significantly lower, and no obvious abnormal heart rhythm or serious liver damage has been found. Doctors can often alleviate adverse effects by adjusting the dose or discontinuing the drug for a short period of time.

Reference materials:https://www.asymbio.com.cn/